Navigation Links
American Scientific Resources Retains National PR/IR Firm
Date:7/5/2011

WESTON, Fla., July 5, 2011 /PRNewswire/ -- American Scientific Resources, Inc. ("American Scientific Resources") (OTCQB: ASFX) today announced it has retained Martin E. Janis & Company, Inc., the 61-year old Chicago-based public relations/investor relations firm, to carry out a fully-integrated marketing and communications program for the company and its products.

(Logo: http://photos.prnewswire.com/prnh/20110124/NY34439LOGO)

The firm will be responsible for working with American Scientific Resources to help bring attention to the Company's product lines and will also work directly with company management to introduce the American Scientific Resources, Inc. to potential investors throughout North America.

Martin E. Janis & Company, Inc., founded in 1950, is a full service firm providing its services to public as well as private corporations, trade associations, and government and political entities and individuals.  The company has a particular niche in working with small, undiscovered companies that have unique products and services and the potential to grow into large well-known companies.

About American Scientific Resources, Inc.

American Scientific Resources, Inc. is a purpose-driven consumer product manufacturer specializing in the clinical, home healthcare, infant and juvenile products industries.  The Company sources and designs innovative health and safety products, developing advanced technology and intellectual property.  The Company's products, which include infrared thermometers and safe disposal systems for home use of sharps and needles associated with certain health care issues, are distributed through established relationships in-house and through an ever growing network of leading global healthcare distributors and retailers.  Brands under the American Scientific Resources umbrella include Kidz-Med, Disintegrator Plus and VeraTemp.

For more information, visit the corporate website at www.americansci.com, www.kidzmed.com and www.disintegratorplus.com.

Forward Looking Statements

The information contained herein includes forward-looking statements.  These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.  You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements.  Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity.  We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.  The safe harbor for forward looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact:

Beverly Jedynak
President
Martin E. Janis & Company, Inc.
312-943-1123
bjedynak@janispr.com

Investor contact:
Investor Relations
American Scientific Resources
IR@americansci.com
561-948-4863


'/>"/>
SOURCE American Scientific Resources, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™
2. American Pain Foundation Launches New Educational Campaign, "Explain Your Pain," to Help Hispanic Americans Better Understand Chronic Pain and Pain Management
3. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
4. Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Associations 71st Annual Scientific Sessions
5. Neuland Labs Launches Expanded Peptide Manufacturing Capabilities at 22nd American Peptide Symposium
6. Express Scripts Strives to Make Prescription Drugs Affordable and Accessible to American Families
7. Metabolic Solutions Development Company to Present Recent Findings on the Therapeutic Potential of Increasing Brown Fat in the Treatment of Diabetes at Annual American Diabetes Association Conference
8. American Regent Initiates Voluntary Nationwide Recall of Concentrated Sodium Chloride Injection, USP, 23.4%, 30 mL Single Dose Vial Due to Particulates
9. American Medical Systems Announces Large-Scale, Physician-Led Registry of Penile Implants
10. Unity Management Group, MCC Announce Increased Contracts and Major Installations at US and South American Pharmaceutical Companies
11. Thomson Reuters - NPR Health Poll Finds Three-Quarters of Americans Support Government Insurance Subsidies for Birth Control Pills
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):